UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 16, 2016

 

 

PROVECTUS BIOPHARMACEUTICALS, INC.

(Exact name of registrant as specified in charter)

 

 

 

Delaware		001-36457		90-0031917
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

7327 Oak Ridge Hwy., Knoxville, Tennessee 37931

(Address of Principal Executive Offices)

(866) 594-5999

(Registrant’s Telephone Number, Including Area Code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

---

Item 5.07.

Submission of Matters to a Vote of Security Holders.

 

(a)	Provectus Biopharmaceuticals, Inc. (the “Company”) held its annual meeting of stockholders on Thursday, June 16, 2016.

 

(b)	At the annual meeting, the Company’s stockholders voted on three proposals. A brief description of and tabulation of votes for each proposal are set forth below.

Proposal 1. The Company’s stockholders elected the following directors for a term of one year. There were 87,919,230 broker non-votes with respect to the proposal.

 

Nominee		For				Withheld
Timothy C. Scott, Ph.D.			62,695,679				21,558,476
Eric A. Wachter, Ph.D.			71,813,766				12,440,389
Jan E. Koe			67,939,822				16,314,333
Kelly M. McMasters, M.D., Ph.D.			68,353,568				15,900,587
Alfred E. Smith, IV			69,492,008				14,762,147

Proposal 2. The Company’s stockholders approved the advisory vote on the compensation of the Company’s named executive officers. There were 87,919,230 broker non-votes with respect to the proposal.

 

For		Against		Abstain
48,237,206		32,554,703		3,462,246

Proposal 5. The Company’s stockholders ratified the selection of Marcum LLP as the Company’s independent auditor for 2016. There were no broker non-votes with respect to the proposal.

 

For		Against		Abstain
160,811,048		8,544,036		2,818,301

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 17, 2016